Cytori Therapeutics Inc (NASDAQ:CYTX) has been maintained as a Buy at Maxim Group by research analyst Jason Kolbert in a recent report released today. …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that enrollment has been completed in its US Phase IIb Osteoarthritis trial. The ACT-OA trial is a double-blind randomized, …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that preclinical and mechanistic data from its thermal injury study, performed with support from the Biomedical Advanced Research and …
Cytori Therapeutics Inc (NASDAQ:CYTX) entered into a four year, $17.7 million term loan withOxford Finance LLC.
The first quarter of 2015 has come to a close and companies are still releasing earnings reports. Let’s look back and see which …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced the pricing of a registered direct public offering of Units, with each Unit consisting of one share of …
Cytori Therapeutics Inc (NASDAQ:CYTX) presented data from two preclinical studies funded through its contract with the United States Biomedical Advanced Research and Development Authority …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced today preliminary 12 month follow-up data from the 12 patient investigator initiated Scleradec-I clinical trial conducted by Prof. …
The investment firm Roth Capital was out with a research report on Cytori Therapeutics Inc (NASDAQ:CYTX), following the news that the company's regenerative cell technology system, Celution, has …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, has designated …
